Schneider, Peter (2016): Pharmaceutical pricing and reimbursement reform in Kyrgyzstan. WHO Regional Office for Europe, Copenhagen. ISBN 9789289052191

[img]
Preview
Text
Pharmaceutical pricing and reimbursement reform in Kyrgyzstan.pdf

Download (1MB) | Preview

Abstract

This report explores the causes of high out-of-pocket (OOP) payments for outpatient medicines in Kyrgyzstan and develops policy recommendations to reduce them. The analysis consisted of a review of current reimbursement mechanisms and an assessment of their ability to protect the Kyrgyz population from high OOP payments. The analysis showed that Kyrgyz patients have been confronted with increasing co-payments for reimbursed medicines in the outpatient sector. Compared to the 2013 figures, co-payments for medicines prescribed and dispensed under the reimbursed drug package increased by 20 % in 2015. A contributing factor for this increase is the absence of price regulation for medicines. Another reason for observed Price increases may be related to currency devaluation. Based on the findings of the analysis, this report proposes several policy options to address high OOP payments, including: introduction of price regulation including control of retail margins, Review of reimbursement processes, strengthening of information systems for monitoring and evaluation, and capacity building of the stakeholders. In Zusammenarbeit mit der Weltgesundheitsorganisation, Regionalbüro für Europa (WHO Regional Office for Europe) hat das WHO-Kooperationszentrum für Arzneimittelpreisbildung und -erstattung an der GÖG eine Untersuchung zur Arzneimittelpolitik in Kirgistan (Zentralasien) durchgeführt. Ziel der Studie war es, Ursachen steigender Zuzahlungen für Patientinnen und Patienten in Kirgistan zu identifizieren und mögliche Ansatzpunkte für Reformen im kirgisischen Arzneimittelsystem vorzuschlagen. Qualitative und quantitative Datenerhebungen wurden Ende Mai/Anfang Juni 2016 von einem multidisziplinären Projektteam der GÖG und WHO Europa vor Ort durchgeführt, und die Ergebnisse der Untersuchung wurden im September in Bischkek bei einem High-Level-Dialog der maßgeblichen Akteure vorgestellt.

Item Type: Book
Subjects: OEBIG > Pharmaoekonomie
Date Deposited: 22 Jun 2017 13:10
Last Modified: 22 Jun 2017 13:10
URI: https://jasmin.goeg.at/id/eprint/62